ArticleBiomaterials2011
3D in vitro bioengineered tumors based on collagen I hydrogels.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 301 citations in OpenAlex.
- Natural Killer Cell Immunotherapy in Solid Tumors: Microenvironmental Obstacles and Translational 3D Models.Biology · 2026Review
- Genipin-Crosslinked, Silane-Anchored 3D Tumor-Stroma Microtissues for High-Content On-Chip Drug Testing.Advanced healthcare materials · 2026Article
- Using biomaterial-based 3D in vitro cancer models to solve current clinical problems.British journal of cancer · 2026Review
- The critical role of hydrogels as an advanced polymeric scaffold in biomedicine: recent progress and challenges.RSC advances · 2026Review
- Recapitulating patient-to-patient colorectal cancer tumor heterogeneity using patient-derived xenograft cells in an engineered tissue model.Acta biomaterialia · 2026Article
- Article
- Reduced graphene oxide-incorporated gelatin-oxidized polymannose scaffold-based 3D Lung cancer model for mimicking the tumor microenvironment.Frontiers in oncology · 2026Article
- Evaluation of 3D biomimetic microcarriers for enhancing therapeutic efficacy of human umbilical cord mesenchymal stem cells in psoriasis treatment.Frontiers in immunology · 2026Article
- Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology.Advanced healthcare materials · 2026Review
- Recapitulating Patient-to-Patient Colorectal Cancer Tumor Heterogeneity Using Patient-Derived Xenograft Cells in an Engineered Tissue Model.bioRxiv : the preprint server for biology · 2025Article
- Review
- Small Extracellular Vesicle Treatment of Trabecular Meshwork Fibrosis: 2D/3D In Vitro and In Vivo Analyses.Investigative ophthalmology & visual science · 2025Article
- Core-Shell Hydrogels with Tunable Stiffness for Breast Cancer Tissue Modelling in an Organ-on-Chip System.Gels (Basel, Switzerland) · 2025Article
- Reproducible extracellular matrices for tumor organoid culture: challenges and opportunities.Journal of translational medicine · 2025Review
- Designing Porosity-Tailored Hydrogel Sponges with Controlled Cell Positioning Using Dispersible, Autofragmented Sacrificial Microfibers.ACS omega · 2025Article
- Toward Bioactive Hydrogels: A Tunable Approach via Nucleic Acid-Collagen Complexation.Regenerative engineering and translational medicine · 2024Article
- Tumor-Infiltration Mimicking Model of Contaminated Ovarian Tissue as an Innovative Platform for Advanced Cancer Research.The AAPS journal · 2024Article
- Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.Advanced healthcare materials · 2024Review
- Characterization of two different alginate-based bioinks and the influence of melanoma growth within.Scientific reports · 2024Article
- Liver-tumor mimics as a potential translational framework for planning and testing irreversible electroporation with multiple electrodes.Bioengineering & translational medicine · 2024Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cells cultured within a three-dimensional (3D) in vitro environment have the ability to acquire phenotypes and respond to stimuli analogous to in vivo biological systems. This approach has been utilized in tissue engineering and can also be applied to the development of a physiologically relevant in vitro tumor model. In this study, collagen I hydrogels cultured with MDA-MB-231 human breast cancer cells were bioengineered as a platform for in vitro solid tumor development. The cell-cell and cell-matrix interactions present during in vivo tissue progression were encouraged within the 3D hydrogel architecture, and the biocompatibility of collagen I supported unconfined cellular proliferation. The development of necrosis beyond a depth of ~150-200 μm and the expression of hypoxia-inducible factor (HIF)-1α were demonstrated in the in vitro bioengineered tumors. Oxygen and nutrient diffusion limitations through the collagen I matrix as well as competition for available nutrients resulted in growing levels of intra-cellular hypoxia, quantified by a statistically significant (p < 0.01) upregulation of HIF-1α gene expression. The bioengineered tumors also demonstrated promising angiogenic potential with a statistically significant (p < 0.001) upregulation of vascular endothelial growth factor (VEGF)-A gene expression. In addition, comparable gene expression analysis demonstrated a statistically significant increase of HIF-1α (p < 0.05) and VEGF-A (p < 0.001) by MDA-MB-231 cells cultured in the 3D collagen I hydrogels compared to cells cultured in a monolayer on two-dimensional tissue culture polystyrene. The results presented in this study demonstrate the capacity of collagen I hydrogels to facilitate the development of 3D in vitro bioengineered tumors that are representative of the pre-vascularized stages of in vivo solid tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.